HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
PNTG
The Pennant Group, Inc.
PNTG's fundamentals are strong and it looks cheap: trading at 36x earnings, below its usual 46x. Analysts expect earnings growth.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
PNTG Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Stable | |
| Stable |
PNTG's revenue and profitability are currently healthy, and its cash flow and balance sheet are stable.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
PNTG PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 24x | $35.91 | — |
| Cheap | 35x | $35.37 | -1.5% |
| Current | 36x | $35.91 | — |
| Fair | 46x | $45.65 | +27% |
| Expensive | 87x | $86.68 | +141% |
Historical ranges are pointers, not guarantees.
PNTG's PE is in its cheap range at 36x. If earnings grow as analysts expect, today's price would be 24x next year's earnings.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
PNTG Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| High |
PNTG has the edge over HIMS on the outlook, with more favorable earnings expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
PNTG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.52 | +52% |
| Q3 2026 | $1.00 | +33% |
| Q2 2026 | $0.91 | +17% |
| Q1 2026 | $0.86 | +13% |
| Q4 2025 | $0.84 | +20% |
| Q3 2025 | $0.75 | +10% |
| Q2 2025 | $0.78 | +24% |
| Q1 2025 | $0.76 | +41% |
| Q4 2024 | $0.70 | +59% |
PNTG has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over PNTG on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
PNTG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $302.3M | +32% |
| Q2 2026 | $298M | +36% |
| Q1 2026 | $285.4M | +36% |
| Q4 2025 | $289.3M | +53% |
| Q3 2025 | $229M | +27% |
| Q2 2025 | $219.5M | +30% |
| Q1 2025 | $209.8M | +34% |
| Q4 2024 | $188.9M | +29% |
PNTG's revenue has grown year over year every quarter since late 2020: $302M last quarter, up 32% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.5% | +1 points |
| Q2 2026 | 5.8% | +0.5 points |
| Q1 2026 | 6.1% | 0 points |
| Q4 2025 | 6% | +1.2 points |
| Q3 2025 | 4.5% | -1.5 points |
| Q2 2025 | 5.3% | -0.4 points |
| Q1 2025 | 6% | +0.6 points |
| Q4 2024 | 4.9% | -0.3 points |
PNTG has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over PNTG on cash flow, with more consistent year-over-year improvement.
PNTG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $10.1M | -3.2% |
| Q2 2026 | $15.5M | -51% |
| Q1 2026 | -$8.7M | +$14.5M |
| Q4 2025 | $17.4M | +0.9% |
| Q3 2025 | $10.5M | +54% |
| Q2 2025 | $31.6M | +256% |
| Q1 2025 | -$23.2M | -$20.6M |
| Q4 2024 | $17.2M | +511% |
PNTG generated $34M in free cash flow over the past year, down 4.9% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over PNTG on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
PNTG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +427K shares |
| 1 year | +3.2% | +1.1M shares |
| 3 years | +20% | +6.2M shares |
| 5 years | +19% | +5.8M shares |
| Available history | +23% | +6.8M shares |
PNTG has 36M diluted shares, up 3.2% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2021 | — |
| Q3 2021 | — |
| Q4 2020 | — |
| Q3 2020 | $8,000 |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
PNTG Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.2x | Moderate |
| Q2 2026 | 2.5x | Moderate |
| Q1 2026 | 2.4x | Moderate |
| Q4 2025 | 2.5x | Moderate |
| Q3 2025 | 0.5x | Very low |
| Q2 2025 | 0.4x | Very low |
| Q1 2025 | 1.0x | Very low |
| Q4 2024 | -0.6x | Net Cash |
PNTG's net debt is about 2.2 years of its operating earnings (EBITDA), up from less than a year a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
PNTG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.9 | Neutral |
| Stochastic | 27.8 | Neutral |
PNTG's weekly RSI is 45 (neutral) and its Stochastic is 28 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
PNTG PE vs Healthcare Sector
| Metric | PNTG | Sector median | Relative |
|---|---|---|---|
| PE | 36x | 26x | 39% above |
| PE % | 18 | 29 | 11 pts below |
PNTG is trading at 36x earnings, a 39% premium to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
PNTG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.7 | 9.5% below |
| 20 week MA | $39.6 | 9.2% below |
| 50 week MA | $34.7 | 3.6% above |
| 100 week MA | $30.2 | 19% above |
| 200 week MA | $24.5 | 46% above |
PNTG has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
PNTG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $32.2 | $61.0 | +90% |
| 2021 | $61.0 | $21.9 | -64% |
| 2022 | $21.9 | $9.95 | -55% |
| 2023 | $9.95 | $13.9 | +40% |
| 2024 | $13.9 | $26.6 | +91% |
| 2025 | $26.6 | $29.1 | +9.1% |
| 2026 YTD | $29.1 | $35.9 | +24% |
PNTG has the edge over HIMS on returns for 2026, with the stronger performance.